Oh by the way. The November 30 D&B report is out
Post# of 11803
(Total Views: 596)
Posted On: 12/05/2019 2:39:52 PM
Oh by the way. The November 30 D&B report is out for Pharma Tech. The latest report summary I just received.
PHARMA TECH SOLUTIONS, INC.
Summary - 12/05/2019
Scores / Ratings Monthly Change
PAYDEX® No Change
Delinquency Predictor No Change
Financial Stress Score No Change
Supplier Evaluation Rating No Change
D&B Rating® No Change
D&B Viability Rating No Change
A lesson for the consultant to all of the companies in the diabetic test strip space, oh and I guess for penny stock traders too: if a company is going down the tubes as the consultant states, then the swirl down the tubes would be reflected in the D&B Summary. Pharma Tech, DECN's operating division, is doing fine. They need some cash, that's all.
I do not follow the DECN D&B Report because that company does not have any specific operations except to manage Pharma Tech, the operating company, and Decision IT the holder of the intellectual property. But hey, penny stock traders probably know better than me.
As my good friend Barbara Asbell has said, managers should manage, salesman should sell, engineers should engineer, and stock traders should buy and sell stock, and never the 'twain shall meet, because when it does it is like mater and anti-matter.
PHARMA TECH SOLUTIONS, INC.
Summary - 12/05/2019
Scores / Ratings Monthly Change
PAYDEX® No Change
Delinquency Predictor No Change
Financial Stress Score No Change
Supplier Evaluation Rating No Change
D&B Rating® No Change
D&B Viability Rating No Change
A lesson for the consultant to all of the companies in the diabetic test strip space, oh and I guess for penny stock traders too: if a company is going down the tubes as the consultant states, then the swirl down the tubes would be reflected in the D&B Summary. Pharma Tech, DECN's operating division, is doing fine. They need some cash, that's all.
I do not follow the DECN D&B Report because that company does not have any specific operations except to manage Pharma Tech, the operating company, and Decision IT the holder of the intellectual property. But hey, penny stock traders probably know better than me.
As my good friend Barbara Asbell has said, managers should manage, salesman should sell, engineers should engineer, and stock traders should buy and sell stock, and never the 'twain shall meet, because when it does it is like mater and anti-matter.
(3)
(0)